Professor Chris Molloy | Image Credit: Medicines Discovery Catapult
Medicines Discovery Catapult (MDC) announces that Professor Chris Molloy will step down from his role as Chief Executive Officer (CEO), a position he has held since the establishment of MDC in 2016.
Dr Mike Strange will lead the company as Interim CEO from the end of January, assuming the role from his current position as Managing Director.
Professor Molloy will support a smooth transition of leadership and strategic programmes at MDC before he takes up the position of CEO at the UK’s BioIndustry Association in May 2026.
Under Professor Molloy’s impactful tenure, MDC has established itself as a unique and vital presence with the UK medicines discovery community, working with the sector to make every move count. Its vision to reshape drug discovery remains steadfast, delivering on its purpose to transform great UK science into better treatments through partnership.
